Published in Hepatitis Weekly, December 8th, 2003
According to a study from Spain, "modification of the pharmacokinetic profile of interferon-alpha (IFN-alpha) through pegylation (addition of a polyethylenglicol molecule) has resulted in a marked improvement of drug efficacy for the treatment of infection due to hepatitis C virus. Two pegylated derivatives of IFN-alpha are available: PEG-IFN-alpha-2a, with a 40-kDa polyethylenglicol molecule of branched structure, and PEG-IFN-alpha-2b, with a 12 kDa linear PEG."
"Both compounds have slower absorption, more reduced distribution and lower elimination rate than the respective...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.